Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Terminal Illness

Illness expected to result in death within a defined prognosis window (often six to twelve months). Cannabis has moderate evidence for managing common end-of-life symptoms (pain, nausea, anorexia, anxiety, sleep disturbance) and is a qualifying condition under most state medical cannabis programs without further diagnosis-specific gating.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelModerateICD-10: Z51.5

What is Terminal Illness?

Terminal illness is a clinical designation for a disease or condition expected to result in death within a defined prognosis window. Most state hospice and end-of-life provisions use a six-month or twelve-month survival expectancy threshold, certified by the treating physician. Common diagnoses in this category include advanced cancer, end-stage organ failure (heart, lung, liver, kidney), late-stage neurodegenerative disease, and amyotrophic lateral sclerosis (ALS).

End-of-life care prioritizes symptom management and quality of life over curative treatment.

Does cannabis help Terminal Illness?

The 2017 NASEM consensus report identified evidence supporting cannabis use for several common end-of-life symptoms: substantial evidence for chronic pain in adults, substantial evidence for chemotherapy-induced nausea and vomiting, moderate evidence for sleep disturbance, and limited evidence for cancer-associated cachexia.

Terminal illness or hospice status is a qualifying condition under nearly every comprehensive US medical cannabis program. Many states with otherwise narrow qualifying-condition lists (including Texas, Georgia, and Alabama) include terminal diagnoses as a baseline access pathway. Certification typically requires the patient's primary physician to confirm prognosis; states differ on whether a second-opinion physician is also required.

Eligibility

State eligibility for Terminal Illness

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Terminal Illness: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Yes	Florida OMMU
Georgia	Yes	Georgia DPH Low-THC Registry
Texas	Not listed	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

What evidence supports cannabis use in end-of-life care?

Moderate, for symptomatic management. End-of-life symptoms most commonly addressed with cannabis (pain, nausea, anorexia, anxiety, sleep disturbance) overlap with conditions for which NASEM identified substantial or moderate evidence (chronic pain, chemotherapy-induced nausea and vomiting, HIV/AIDS-associated wasting). Terminal-illness-specific trials are limited, but the underlying symptom-domain evidence is reasonably strong.

Is any cannabis-derived product FDA-approved for end-of-life or palliative use?

Two synthetic cannabinoids, dronabinol (Marinol) and nabilone (Cesamet), are FDA-approved for chemotherapy-induced nausea and vomiting that has failed conventional antiemetics. Dronabinol is also approved for anorexia associated with weight loss in patients with AIDS. Plant cannabis is not FDA-approved for any terminal-illness or palliative indication.

How does prognosis-window definition vary across state medical-cannabis programs?

State statutes use different prognosis thresholds for the "terminal illness" qualifier. Some require a six-month life-expectancy certification (paralleling federal hospice criteria); others use twelve months; a number of states use open-ended language tied to the certifying physician's judgment without a fixed window. There is no universal national standard.

What practical considerations apply for hospice and palliative-care patients?

Drug interactions with palliative-care medications (opioids, benzodiazepines, antiemetics, sedatives) are common; additive sedation is the most frequent concern. Inhaled cannabis may be impractical or contraindicated in patients with respiratory compromise. Tinctures, edibles, and oils are commonly used. Coordination with the hospice or palliative-care team is important, both for symptom control and for any cross-jurisdictional access concerns when patients move between care settings.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.